These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. Kitagawa M; Yoshida S; Kuwata T; Tanizawa T; Kamiyama R Am J Pathol; 1994 Aug; 145(2):338-44. PubMed ID: 8053492 [TBL] [Abstract][Full Text] [Related]
46. [Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR]. Gu WY; Chen ZX; Cao XS; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):728-31. PubMed ID: 15730716 [TBL] [Abstract][Full Text] [Related]
47. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia. Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451 [TBL] [Abstract][Full Text] [Related]
48. [The implications of the biological indices examination of bone marrow cells in myelodysplastic syndromes]. Zhang F; Hao Y; Pang W Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):528-32. PubMed ID: 11769678 [TBL] [Abstract][Full Text] [Related]
49. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome]. Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904 [TBL] [Abstract][Full Text] [Related]
50. Proposals for the classification of the myelodysplastic syndromes. Bennett JM; Catovsky D; Daniel MT; Flandrin G; Galton DA; Gralnick HR; Sultan C Br J Haematol; 1982 Jun; 51(2):189-99. PubMed ID: 6952920 [TBL] [Abstract][Full Text] [Related]
51. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058 [TBL] [Abstract][Full Text] [Related]
52. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751 [TBL] [Abstract][Full Text] [Related]
53. Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome. Qian J; Chen Z; Wang W; Cen J; Xue Y Oncol Rep; 2005 Nov; 14(5):1189-97. PubMed ID: 16211284 [TBL] [Abstract][Full Text] [Related]
54. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969 [TBL] [Abstract][Full Text] [Related]
55. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365 [TBL] [Abstract][Full Text] [Related]
56. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598 [TBL] [Abstract][Full Text] [Related]
57. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841 [TBL] [Abstract][Full Text] [Related]
58. Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). Economopoulou C; Pappa V; Papageorgiou S; Kontsioti F; Economopoulou P; Charitidou E; Girkas K; Kapsimali V; Papasteriadi C; Tsirigotis P; Papageorgiou E; Dervenoulas J; Economopoulos T Ann Hematol; 2010 Apr; 89(4):349-58. PubMed ID: 19813013 [TBL] [Abstract][Full Text] [Related]
59. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes. Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099 [TBL] [Abstract][Full Text] [Related]
60. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset]. Sugiyama H Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]